Melanoma enzyme study could unlock secrets of treatment resistance

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * group 1: patients with primary thin melanoma (Breslow thickness less than or equal to1 mm) monitored for 10 years, having relapsed or not within 10 years after the diagnosis. * patients with no other concomitant cancers requiring systemic treatment at the time of diagnosis of primary melanoma * patient or patient's family (in case of death) informed of the objectives and modalities of the study and not opposed to participation in the study * patient or patient's family (in case of death) not opposed to the use of part of the skin sample previously taken for the present research * group 2: patients with primary thick melanoma (Breslow greater than or equal to 3 mm) monitored for 5 years, having relapsed or not within 5 years after diagnosis. * patient with no other concomitant cancers requiring systemic treatment at the time of diagnosis of primary melanoma * patient or patient's family (in case of death) informed of the objectives and modalities of the study and not opposed to participation in the study * patient or patient's family (in case of death) not opposed to the use of part of the skin sample previously taken for the present research * group 3: patient with melanoma (stages III or IV inoperable) and who are treated with immunotherapy and / or biotherapy * patient with no other concomitant cancers requiring systemic treatment at the time of diagnosis of primary melanoma and initiation of systemic treatment for melanoma * patient informed of the objectives and modalities of the study and having given informed and written consent to participate in the study Exclusion Criteria: * groups 1 and 2: patient or family of the patient opposed (e) that part of the primary melanoma taken previously is used in the context of the present project * group 3 : * refusal of the patient to participate in the study * patient unable to understand the study and sign consent * patient with a known contraindication to xylocaine * patient not affiliated to a social security system (beneficiary or beneficiary's right) * adult subject to a legal protection measure